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Abstract: MYC is a transcription factor that is involved in the expression of many genes. 
Deregulated MYC is found in about half of human tumors, being more prevalent in hematologi-
cal neoplasms. Deregulation mechanisms include chromosomal translocation (particularly in 
lymphoma), amplification, and hyperactivation of MYC transcription. Here we review MYC 
involvement in the major types of leukemia and lymphoma. MYC rearrangements appear in all 
Burkitt lymphomas and are common in other lymphoma types, whereas in acute lymphoblastic 
leukemia, acute myeloid leukemia, lymphoproliferative, and myeloproferative diseases, they are 
less frequent. However, MYC overexpression is present in all types of hematological malignancies 
and often correlates with a worse prognosis. Data in leukemia-derived cells and in animal models 
of lymphomagenesis and leukemogenesis suggest that MYC would be a good therapeutic target. 
Several MYC-directed therapies have been assayed in preclinical settings and even in clinical 
trials. First, peptides and small molecules that interrupt the MYC–MAX interaction impair MYC-
mediated tumorogenesis in several mouse models of solid tumors, although not yet in lymphoma 
and leukemia models. Second, there are a number of small molecules inhibiting the interaction of 
MYC–MAX heterodimers with DNA, still in the preclinical research phase. Third, inhibitors of 
MYC expression via the inhibition of BRD4 (a reader of acetylated histones) have been shown 
to control the growth of MYC-transformed leukemia and lymphoma cells and are being used in 
clinic trials. Finally, we review a number of promising MYC-mediated synthetic lethal approaches 
that are under study and have been tested in hematopoietic neoplasms.
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Introduction
Hematological neoplasms are the result of the malignant transformation of a hematopoi-
etic cell at a specific stage of differentiation. Morphologic characterization has tradi-
tionally been the gold standard technique for the identification of the different types, 
but improvement on the molecular methodologies revealed that those subtypes are 
composed of many different molecular subtypes. In fact, many malignancies are nowa-
days classified based on a specific genetic abnormality or a transcriptional signature.1 
There are, however, other nonspecific genetic aberrations, associated with particular 
biological and clinical implications. Such is the case of MYC, which is deregulated 
in many different subtypes of lymphoma and leukemia, sometimes as a primary event 
(eg, Burkitt lymphoma [BL]) or as a secondary event that usually implies aggressive-
ness and poor prognosis.
MYC (also called c-Myc) is an oncogenic transcription factor of the helix-loop-
helix-leucine zipper family. MYC is deregulated in half of the human tumors, including 





leukemia and lymphoma.2–5 MYC forms dimers with MAX 
through the leucine zipper (LZ) domain. The MYC–MAX 
heterodimer is the active form which binds to specific DNA 
sequences (E-boxes, canonical sequence CACGTG) in the 
regulatory regions of target genes. The number of MYC-
binding sites revealed by genome-wide technologies ranks 
between 7,000 and 15,000 in different models. Indeed, MYC 
is bound at one or more sites of the regulatory regions of 
10%–15% of human genes and, as expected, there is a large 
number of MYC-regulated genes, reaching the staggering 
number of 1,000 genes in most models.6–8
The mechanism for MYC-mediated transactivation 
depends on the recruitment of complexes containing 
histone acetyltransferases.7,9 Recent work has shown that 
MYC is present at the promoter of nearly all active genes 
acting as an “amplifier” of the transcription intensity of 
genes already engaged in transcription.10 The mechanism 
is not well known, but the activating interaction of MYC 
with P-TEFb (positive transcription elongation factor b) 
likely plays an important role.11,12 However, the extent of 
MYC binding to chromatin depends on the level of MYC in 
the cell, and MYC overexpression provokes an “invasion” 
of new E-boxes, either in proximal promoters or at distal 
enhancers, so that a new set of genes are overexpressed. 
It is still unclear to what extent MYC contributes to the 
overexpression of these new “invaded” genes,13,14 but it is 
established that upon MYC induction or activation, the 
expression of a series of “MYC target genes” become 
overexpressed with respect to most other genes of the 
cell, whereas others (eg, the genes of cell cycle inhibitors 
CDKN1A and CDKN2B) are downregulated.14,15
In agreement with the large number of regulated genes, 
overexpression of MYC impinges on a series of functions 
that confer ample competitive advantages to the cell, such as 
cell cycle stimulation, nucleotide biosynthesis, differentia-
tion impairment, energy production, protein synthesis and 
ribosome genesis, genomic instability, immortalization, and 
telomere maintenance or block of differentiation.3,7,8,15,16 All 
these combined functions contribute to – or trigger – the 
development of hematological neoplasia (Figure 1). Indeed, 
MYC oncogene was originally discovered as the oncogene 
carried by retroviruses that induced a myeloid neoplasm in 
chicken, ie, myelocytomatosis, and MYC was named after 
this tumor.17 Moreover, BL was the first human tumor where 
MYC deregulation was identified, due to a chromosomal 






















Figure 1 Major biological activities elicited by deregulated MYC that contribute to the development and progression of leukemia and lymphoma.
Note: Data from multiple sources.3,7,8,15,16
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cells” section. In this review, we will first summarize MYC 
involvement in the major lymphoid and myeloid neoplasms 
and then the different approaches using MYC as a target in 
these neoplasms.
MYC and lymphoid neoplasms
The first animal model generated for MYC-driven cancer was 
the Eµ-Myc transgenic mouse, in which MYC expression 
is targeted to the lymphoid compartment by the immuno-
globulin (Ig) heavy chain gene promoter and enhancer.18,19 
The model demonstrated the ability of MYC to transform B 
cells in mice, although, as discussed in “Burkitt lymphoma” 
section, the tumors do not faithfully reproduce BL.
MYC plays key roles in different stages of the antigen- 
dependent B-cell differentiation process. On encounter with 
the antigen-dependent T-cell, the naïve B-cell moves to a fol-
licle where it intensely proliferates to form a germinal center. 
MYC upregulation is essential to induce this migration, and 
indeed, MYC-deficient mice lack the ability to induce these 
germinal center reactions. Those lymphocytes that enter the 
dark zone of the germinal center start expressing BCL6, 
which in turn represses MYC expression. Once the somatic 
hypermutation (SHM) process is complete, those cells move 
to the light zone and are selected for the production of high 
affinity antibodies. Those B-cells that fail selection die by 
apoptosis, whereas those producing high affinity antibod-
ies, will either return to the dark zone for a further round of 
SHM, which requires MYC expression, or exit the germinal 
center, either as an antibody producing cell (plasma cell) or 
as a memory B-cell (schematized in Figure 2). Germinal 
centers, therefore, contain highly proliferating B-cells that 
are undergoing mutations mediated by activation-induced 
deaminase (AID), and thus they might be predisposed to 
malignant transformation. In fact, a significant number of 
B-cell aggressive lymphomas emerge from these areas,20 
and a considerable proportion of those will show MYC 
translocation. Interestingly, mice lacking AID do not develop 
IGH–MYC translocations.21 MYC involvement in lymphoid 
neoplasms is summarized in Table 1.
Neoplasms of lymphoid precursors
Neoplasms of T-cell precursors
Adult T-cell acute lymphoblastic leukemia (T-ALL) is asso-
ciated with poor prognosis with standard chemotherapy-
based regimens. MYC translocations are detected in 6% of 
T-ALLs, usually as secondary events, and associated with 
induction failure and relapse.22 Notch signaling pathway, 
which is deregulated in more than 50% of T-ALL, has been 
shown to directly upregulate MYC. Also, MYC binding 
to a NOTCH1-enhancer is required for NOTCH1-induced 
T-ALL.23 In vitro treatment of T-cell lines with valproic acid 
(a histone deacetylase inhibitor) led to downregulation of 
MYC in a dose-dependent manner and, specific inhibition 
of MYC function was shown to further increase cell death in 
those cell lines.24 Xenograft models have also demonstrated 
that MYC inhibition eliminates the leukemia-initiating cells 
(LICs) and inhibits growth of pediatric T-ALL cells.25 This 
effect might be more efficient when MYC inhibitors are 
used in combination with either chemotherapy regimens26 
and/or with inhibitors of other pathways such as PI3K.27 
Nevertheless, those combinations are yet to be assayed in 
specific subtypes.
Neoplasms of B-cell precursors
Pediatric B precursor acute lymphoblastic leukemia (ALL) is 
in most cases a curable disease with intensive  chemotherapy. 
Still, 20%–30% of patients will undergo induction failure 
or relapse. Also, adult ALLs, usually associated with mixed 
lineage leukaemia (MLL) or BCR–ABL rearrangements, 
have a poor expectancy even with allogenic bone marrow 
transplantation. Approximately 2%–5% of ALLs show 
MYC rearrangements,28 and a number of B-cell acute lym-
phoblastic leukemia (B-ALL), while not having MYC gene 
abnormalities show high MYC expression.29 Cell cycle arrest 
is achieved using bromodomain and extra-terminal (BET) 
inhibitors in variety of MYC-expressing ALLs in vitro (see 
“Epigenetic-based MYC therapy: anti BRD4 drugs” section). 
Also, in vivo responses were observed in ALL xenograft 
models when BET inhibitors were used alone or in combina-
tion with dexamethasone.29
Neoplasms of mature B-cells
MYC deregulation may be observed in any type of mature 
lymphoid neoplasm, although it is more frequently observed 
in the aggressive lymphoma types. It may act as a driver 
abnormality such as in BL, but in many cases, appears as a 
secondary event, indicating clonal evolution and/progression. 
MYC is a frequent target of chromosomal translocations in 
lymphomas with different partners, the immunoglobulin 
heavy chain locus being the most common. As a result of 
these rearrangements, transcription of the unaltered MYC 
coding region is controlled by the regulatory sequences of 
the partner gene (promoter substitution), leading to deregu-
lated MYC expression. Other mechanisms involved in MYC 
deregulated expression in neoplasms include amplification, 
insertional mutagenesis, and upregulation of certain signaling 





pathways that impinge in the hyperactivation of MYC pro-
moter. Although MYC amplification has been described in 
many tumors and is often related to tumor progression, it must 
be noted that recent reports show that the coamplification of 
the adjacent gene PVT1, coding for a lncRNA, cooperates 
with MYC-driven tumorigenesis.30
Burkitt lymphoma
Animal models have shown us the relevance of MYC deregu-
lation in B-cell malignancies. The lymphomas generated in the 
original Eµ-Myc transgenic mice (the first model for MYC-
induced cancer) do not reproduce BL well,18,19 but additional 
transgenic mouse cell lines have been generated that better 
reproduce BL. These models for BL include models of mice 
carrying a single copy of the 240-kb IgH/c-Myc translocation 
region,31 mice carrying the murine Myc cDNA inserted in 
the IgH locus in a site that correspond to the human t(8;14) 
translocation break,32 mice with MYC linked to the 3′ IgH 
locus control region (3′ LCR),33 or mice with combined MYC 









































































Figure 2 MYC roles in lymphoid differentiation and in lymphoid neoplasms.
Notes: (A) MYC is required for correct self-renewal/differentiation balance of LT-HSC. (B) MYC is required for the expansion of pro-B cells to pre-B cells. (C) MYC is 
expressed in B cells after interaction with antigens, being essential for GC formation. BCL6 upregulation on germinal center cells will inhibit MYC expression. (D) MYC is 
re-expressed in a subset of cells of the light zone, due to NFκB-iRF4 upregulation, that will reenter into the dark zone to undergo a second round of somatic hypermutation. 
(E) MYC is also required for DN expansion to DP lymphocytes. The cellular origin of the main lymphoid neoplasms is indicated.
Abbreviations: ALL-B, B-acute lymphocytic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALCL, anaplastic large cell lymphoma; BCLU, B-cell lymphoma 
unclassifiable; BL, Burkitt lymphoma; GC, germinal center; GCB,  germinal center B-cell; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; BCLU, 
B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL; DZ, dark zone; LZ, light zone; LT-HSC, long-term hematopoietic stem cells; MCL, mantle 
cell lymphoma; MM, multiple myeloma; DN, double negative; DP, double positive; FL, follicular lymphoma; PBL, plasmablastic lymphoma.
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Although BL is the most frequent subtype of lymphoma in 
children, in terms of total number of cases is more common 
in adults. IG–MYC rearrangements, while not being specific, 
constitute the hallmark of this lymphoma, being detected in 
more than 90% of cases, frequently as a single anomaly. More 
than 80% of cases will show a t(8;14)(q24;q32) (IGH-MYC), 
and the remaining cases will present either a t(8;22)(q24;q11) 
(IGL-MYC) or a t(2;8)(p12;q24) (IGK-MYC).35,36 Cases with 
no detectable translocation might represent failure to detect 
small rearrangements, but it is still a matter of debate whether 
true BL without MYC translocation exists. A non-rearranged-
MYC-endemic BL type has been proposed to be the result of 
downregulation of a microRNA (hsa-mir-34b) that silences 
MYC expression.37 Recently, some atypical BL cases lacking 
MYC-rearrangement have been shown to present a peculiar 
pattern of chromosome 11q aberrations.38
Three subtypes of BL showing different clinical and 
biological features have been described: endemic, sporadic, 
and immunodeficiency-associated. The endemic is the most 
frequent type of lymphoma in children in Africa, and IGH–
MYC in this subtype arise from either aberrant hypermutation 
process or might occur during the VDJ (variable, diverse, and 
joining gene segments) recombination process. In contrast, 
in sporadic and immunodeficiency-associated types, gene 
breakpoints generally affect the IGH switch regions.39
MYC deregulation is known to be necessary but not suf-
ficient to induce the complete BL phenotype. While inducing 
proliferation, MYC also promotes apoptosis mainly through 
activation of both the p53 pathway and by inducing the 
expression of the proapoptotic gene BIM. BL cells have 
been shown to develop different mechanisms to counteract 
these MYC proapoptotic stimuli, such as the impairment 
of BIM function through direct and indirect mechanisms 
including p53 mutations, upregulation of MDM2, or p14ARF 
loss. Another mechanism to elude MYC-induced apoptosis 
is downregulation of the p27Kip mediated by LMP2A, an 
Epstein–Barr virus (EBV) protein.40 Sequencing analysis of 
BL patients have shown a low rate of mutations, but MYC 
is the most frequently mutated gene (up to 70% of cases).41 
Approximately 60% of these mutations result in increased 
stability of the protein via reduced ubiquitin-mediated 
proteolysis.41–43
Additional transforming mechanisms have been described 
to contribute to the pathogenesis of the different subtypes of 
BL. EBV genome is detected in all endemic patients and has 
been shown to cooperate with MYC in the pathogenesis of 
this subtype.44 However, viral infection is only detected in 10% 
and 30% of sporadic and immunodeficiency-associated cases, 
respectively. In contrast, sequencing analysis have encoun-
tered mutations of the PI3K pathway (more frequently ID3/
Table 1 MYC in lymphoid neoplasms
Neoplasm MYC involvement References
Precursor lymphoblastic leukemia
 B-ALL MYC levels predict response to BeT inhibitors (5% and 2%–5% in adults and children, respectively) 24,25,28,29
 T-ALL MYC amplification in 6% of cases 
MYC essential for NOTCH1-mediated leukemogenesis
25,156,157
Mature B neoplasms
 BL MYC translocations in .90% cases and mutations in 60%–70% of cases, targeting amino-terminal  
transactivation domains
35,36,41,42,43
 DLBCL MYC translocations in 5%–14% 
MYC amplification in 2% usually as secondary event. Frequently associated to BCL2 and or BCL6  
rearrangements (“double hit” lymphomas)
43,45,46,47
 BCLU MYC translocations, 32%–78% cases, frequently associated to BCL2 and or BCL6 rearrangements 43,46,47
 PBL MYC translocations in 40%–50% cases 
MYC counteracts the antiproliferative BLiMP1 effect
42,158
 FL increased MYC expression, commonly observed in transformed FL to DLBCL (occurring in  
30%–40% of FL)
42,159
 MCL Rare MYC translocations and as secondary events 49
 CLL MYC downregulation in peripheral blood CLL 
MYC translocation and amplifications in ,3% cases 




 MM Translocated in 15%–50% of cases. in many cases involved in complex rearrangements 64,160,161
Mature T neoplasms
 ALCL High levels of MYC, not due to translocations but due to stimulation of the STAT3 pathway 65
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; BeT, bromodomain and extra-terminal; T-ALL, T-cell acute lymphoblastic leukemia; BL, Burkitt lymphoma; 
DLBCL, diffuse large B-cell lymphoma; BCLU, B-cell lymphoma unclassifiable with features intermediate  between DLBCL and BL; PBL, plasmablastic lymphoma; FL, follicular 
lymphoma; MCL, mantle cell lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; ALCL, anaplastic large cell lymphoma.





TCF3 mutations) in 70% of sporadic and immunodeficiency-
associated BL, suggesting that this pathway plays key roles 
in those subtypes of BL. Interestingly, mice models, with 
constitutive activation of both MYC and PI3K, develop a 
lymphoma which morphologically and clinically resembles 
human BL.34
MYC in other aggressive mature B-cell lymphomas
Classification of aggressive lymphomas is becoming very 
complex, since many entities that in the past were thought to 
be single diseases are in reality composed of different types. 
We will now review MYC involvement in the major types 
of aggressive lymphomas.
Diffuse large B-cell lymphoma (DLBCL) is the most fre-
quent subtype of mature B-cell lymphoma in western countries. 
MYC expression is detected in virtually all DLBCLs, but the 
number of positive cells vary from one case to another. Cells 
carrying rearrangements or amplifications of MYC frequently 
show a high fraction of MYC-expressing cells (∼70%), whereas 
only 30% of the lymphomas with less positive cells (30%–40%) 
present MYC gene alterations. Overall, MYC gene rearrange-
ments constitute the third most common aberrancy in this type 
of lymphoma (6%–15% of cases) and confer a bad prognosis.42,45 
They are usually secondary events that appear in the context 
of complex karyotypes and are more frequently detected in 
DLBCL with a germinal center B-cell (GCB) phenotype.45,46
B-cell lymphoma unclassifiable (BCLU) with features 
intermediate between DLBCL and BL is a provisional entity 
described in the latest version of the WHO classification to 
designate those cases that share both clinical and biological 
characteristics between DLBCL and the BL, but that can-
not be clearly assigned to any of those categories.1 Those 
lymphomas frequently resemble BL, have been proven to 
be very aggressive, and show poor response to conventional 
treatments. MYC rearrangements have been reported in 
30%–70% of BCLU cases.47,48
Double hit/triple hit lymphomas refers to those aggres-
sive lymphomas which have simultaneous MYC with BCL2 
and/or BCL6 rearrangements. The phenotype of these 
lymphomas is heterogeneous, sometimes having a DLBCL 
appearance (2%–12%) while others have a BCLU pheno-
type (32%–78%),47 but they all show an aggressive course 
and appear to be resistant to conventional chemotherapy 
regimens. New therapeutic approaches using small molecule 
inhibitors that target MYC and BCL2 are currently under 
investigation.46 MYC rearrangement predicted an inferior 
outcome in aggressive lymphomas in most studies, but it is 
not yet entirely clear if this is due to the MYC rearrangement 
itself or because 50%–80% of MYC-translocated DLBCL 
cases harbor dual or even triple translocations also targeting 
BCL2 and/or BCL6.45–47 The prognostic implication of MYC 
in those patients is difficult to establish since the diagnostic, 
phenotypic, and cytogenetic criteria, together with thera-
peutic approaches are very heterogeneous in the different 
published series.47
An increasing interest on the “double-expressor” (DE) 
large B-cell lymphomas, defined by most groups to have 
approximately 40% MYC and 50%–70% BCL2 cells by 
immunohistochemistry has been recently described. These 
lymphomas have more frequently a non-GCB phenotype and 
whether the identification of these lymphomas helps to prog-
nostically stratify aggressive lymphomas is not clear yet.47
Lymphomas with plasmablastic differentiation include a 
variety of lymphomas which show a plasmatic gene expression 
profiling (with upregulation of PRMD1/BLIMP1 and XBP1). 
All of these together constitute aggressive lymphomas with very 
poor response to conventional treatments. Among these cases, 
plasmablastic lymphoma shows MYC rearrangement in up to 
50% of cases, frequently with the IGH and in context of com-
plex karyotypes. MYC rearrangements have been shown to be 
involved in the pathogenesis of the disease maybe by repressing 
the antiproliferative effect of BLIMP1.42 Plasmablastic lympho-
mas have been proven to respond poorly to conventional CHOP 
(rituximab–cyclophosphamide, doxorubicin, vincristine, and 
prednisone). Whether these types of lymphomas might benefit 
by adding MYC inhibitors requires to be investigated.
MYC in low-grade mature B-cell neoplasms
Mantle cell lymphoma (MCL) is a lymphoproliferative 
disease characterized by a monoclonal proliferation of lym-
phocytes that usually bears an IGH–CCND1 translocation. 
Deregulation of CCND1 (cyclin D1) has been shown not to 
be sufficient to induce lymphomas, and cooperation with 
other oncogenes as MYC is linked to the pathogenesis of 
MCL. MCL blastoid variants frequently show p16INK4a dele-
tion and overexpression of CDK4 and MYC. Consistently, an 
animal model expressing MYC and a mutant CDK4, which 
is resistant to p16 inhibition, develops a lymphoproliferative 
disease with overexpression of CCND1 that resemble MCL, 
including CCND1 overexpression.49
Transformation of follicular lymphoma (FL) to a higher 
grade DLBCL occurs in 10%–60% of the cases. One of 
the genetic abnormalities involved in this process is MYC 
deregulation.50
Regarding MYC expression, chronic lymphocytic leukemia 
(CLL) is an exception in human cancer. Although there are 
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conflicting reports as to the mRNA expression,51,52 our labora-
tory showed that MYC protein expressions in peripheral blood 
of CLL are clearly below that of healthy lymphocytes from 
blood or tonsils, and the small fraction of cases with detectable 
MYC (less than 20%) do not show a difference in the course 
of the disease.52 Amplification and rearrangements of MYC are 
rare in CLL (less than 3%), but when they occur, they correlate 
with a poor prognosis and aggressive disease.53–55 Also, in CLL 
transformation to high-grade lymphoma, known as Richter 
syndrome, MYC upregulation is frequent, similar to other 
aggressive lymphomas.54,56 Thus, MYC gene abnormalities 
in low-grade lymphomas are usually secondary events that 
frequently appear in an event of progression or transformation, 
and thus are associated with an adverse prognosis.
Multiple myeloma
Rearrangements of the MYC oncogene are present in 
15%–50% of primary human multiple myelomas (MMs), 
in many cases involved in complex rearrangements,57,58 
and its activation seems to play a role in the progression 
of plasma cell neoplasms, particularly from monoclonal 
gammopathy of undetermined signif icance (MGUS) 
to plasma cell myeloma. Indeed, MYC rearrangements 
and overexpression are more frequent in MM than in 
MGUS57,59,60 and mark a more aggressive disease.57,61 Fre-
quent upregulation of MYC is also observed in plasma cell 
leukemia, a monoclonal gammopathy which can evolve 
from MM.62 The involvement of MYC in MM is supported 
by the Vk*MYC transgenic mouse, that recapitulate the 
biological and clinical features of human MM. In these 
mice, MYC is under the control of the κ light chain gene.63 
Moreover, MM is one of the neoplasms that respond to 
treatment with BRD4 inhibitors (see “MYC as a target 
in leukemia and lymphoma” section), leading to MYC 
downregulation.64
Neoplasms of mature T-cells
Anaplastic large cell lymphoma (ALCL) is a T-cell neoplasm 
that can be classified into two groups based on the presence 
or absence of ALK gene rearrangements. Both subtypes are 
known to express high levels of MYC, not due to transloca-
tions but due to stimulation of the STAT3 pathway. Moreover, 
pharmacologic inhibition of MYC induced ALCL cell apop-
tosis, and therefore, MYC inhibitors might be an effective 
treatment for ALCL.65
MYC and myeloid neoplasms
As compared to lymphoid neoplasms, MYC involvement in 
myeloid leukemia has been less studied. However, a myeloid 
tumor (myelocytomatosis) was the original tumor caused by 
MYC retroviruses in chicken, and the inhibition of myeloid 
cell differentiation was one of the first biological effects 
described for MYC.16 Moreover, MYC transgenic mice 
models reveal that MYC is an efficient oncogene inducing 
Table 2 MYC in myeloid neoplasms
Neoplasm MYC involvement Reference
AML
MYC amplification (in dmin) 
MYC mRNA overexpression by microarrays analysis 
MYC mRNA overexpression by microarrays (20%) in AML without translocations 
MYCN overexpression (24%–40%) in pediatric AML 
MYC mRNA overexpression (therapy-related AML) 
MYC protein elevated in AML cells cocultured with stroma 









 CML MYC mRNA overexpression over healthy cells 
High MYC mRNA and protein at diagnosis correlated with poor response to imatinib 
MYC protein elevated at diagnosis associated to progression. Altered MYC phosphorylation 





 essential thrombocythemia MYC mRNA overexpression 170
 MPNs progression Trisomy 8 or amplification of 8q24 (MYC) detected in JAK2v617F(–) cases with MPN-blast phase 171
MDS
MYC mRNA upregulation by microarrays or RT-PCR 
MYC amplification (in dmin and hsr) 
Highest MYC expression in AML and in higher-MDS (prognosis marker) 





Abbreviations: dmin, double minute; hsr, homogeneous staining regions; AML, acute myeloid leukemia; MPN, myeloproliferative neoplasm; CML, chronic myeloid leukemia; 
LiCs, leukemia-initiating cells; MDS, myelodisplastic syndrome; RT-PCR, real-time polymerase chain reaction.





acute myeloid leukemia (AML),66,67 and mice with bone 
marrow repopulated with Myc overexpressing cells develop 
an AML-like disease.67 MYC deregulation has been found in 
most types of human myeloid neoplasms, and is reviewed in 
the following section and summarized in Table 2.
Acute myeloid leukemia
AML is a heterogeneous group of neoplasms affecting the 
myeloid lineage. MYC amplification and overexpression 
have been reported in AML. MYC rearrangements are rare 
in AML, and the mechanisms of MYC overexpression are 
not well known. Some leukemogenic transcription factors 
such as RUNX1-RUNX1T1 and PML-RARα induce MYC 
expression.68,69 MYC amplification in AML is infrequent, 
although double minute (dmin) chromosomes and homo-
geneous staining regions (hsr) including the region 8q24, 
where MYC maps, have been described in AML.70,71 MYC 
overexpression in AML induced resistance to chemothera-
peutic drugs.72 Increased MYC levels were correlated with 
decreased microRNA-29 family expression in AML.73
Chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a proliferative clonal 
disorder of hematopoietic stem cells that results in the 
expansion of mature myeloid cells that retain a capacity for 
differentiation. CML, in the absence of treatment, will prog-
ress from the initial chronic phase, to a blastic crisis phase, 
which is a secondary acute leukemia. BCR–ABL kinase has 
a central role in CML etiology.74,75 BCR–ABL upregulates 
MYC expression, which cooperates with BCR–ABL in 
transformation. Consistently, imatinib and other BCR–ABL 
inhibitors provoke downregulation of MYC.76–79 MYC mRNA 
levels are elevated in CML–blastic crisis80,81 and in chronic 
phase CML compared to healthy bone marrow samples.81–83 
Our laboratory showed that MYC is upregulated during CML 
progression.81 High MYC expression correlates with poorer 
response to imatinib and progression to blastic crisis.81,84 
MYC also induces genetic instability and blocks erythroid 
differentiation mediated by imatinib in CML-derived cells77,81 
suggesting that MYC contributes to CML by acting at least 
at those two levels.
In the hematopoietic stem cells population, MYC controls 
the balance between hematopoietic stem cell self-renewal 
and differentiation.5 MYC also plays an important role in 
the establishment and maintenance of LICs. The interaction 
between the ubiquitin ligase Fbw7 and its substrate MYC 
controls the CML LIC homeostasis and has a role in CML 
initiation and progression.85,86
Myelodysplastic syndrome
The myelodysplastic syndromes (MDSs) are characterized 
by both an aberrant differentiation process with morphologic 
evidence of marrow dysplasia and an increased ineffective 
proliferation of the myeloid precursors in bone marrow, with 
enhanced risk of transformation to an AML. Gene expression 
profiles of CD34+ cells from MDS patients showed MYC 
as one of the most upregulated genes in these patients.87 In 
agreement, CD34+ cells from patients with trisomy 8 MDS 
showed upregulation of MYC mRNA.88 MYC amplification 
has also been found in MDS, but with low frequencies.
MYC as a target in leukemia and 
lymphoma
Given its pervasive involvement in leukemogenesis and lym-
phomagenesis, MYC would be an ideal oncoprotein target for 
therapy. The “oncogene addiction” is defined as the phenom-
enon by which some tumors exhibit a dependence on a single 
oncogenic protein or pathway for sustaining growth and 
proliferation.89 MYC addiction was demonstrated in animal 
models for lymphoma and myeloid leukemia, showing that 
inactivation of MYC results in sustained tumor regression.90 
This fact and the overexpression found in many hematologi-
cal neoplasms suggest that silencing or inactivation of MYC 
may be a sensible therapeutic strategy. Indeed, early studies 
established that genetically targeting MYC could control 
leukemogenesis. These studies showed that antisense-MYC 
oligonucleotides reduced the leukemia induced in vivo by 
cell lines derived from BL, CML, and AML.91,92 This was 
confirmed in different reports. In a recent report, MYC sup-
pression by siRNA or pharmacologic approaches was shown 
to prevent leukemia initiation in mice by eliminating LICs of 
human T-cell ALL.25 Importantly, despite widespread expres-
sion of MYC in normal cells and its involvement in many 
biological processes, recent studies have demonstrated that 
long-term, whole-body inactivation of MYC in mouse models 
by expression of a dominant negative MYC form (Omomyc, 
see “MYC as a target in leukemia and lymphoma” section)93,94 
or by treatment with a compound that repress MYC expres-
sion (JQ1)95 only provokes mild side effects.
Altogether, the data suggest that MYC inhibition could 
be a clinically feasible strategy for leukemia and lymphoma 
therapy. However, there also are some drawbacks when target-
ing MYC. First, no adverse effects of MYC inactivation have 
been detected in mouse models studied so far. Second, MYC 
being a transcriptional factor and not an enzyme, it lacks a 
pocket where small molecules can fit. Thus, like many other 
transcription factors, MYC has the reputation of being a 
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“nondruggable” target. Despite that, several approaches have 
targeted MYC, either as a direct target or as an indirect target 
via synthetic lethal approaches. We will briefly review these 
approaches, which are also summarized in Table 3.
epigenetic-based MYC therapy: anti 
BRD4 drugs
Epigenetic mechanisms include histone postranslational 
modifications. Histone N-ter tails are rich in lysine residues 
which can be acetylated by histone lysine acetyltransferases. 
Acetylation neutralizes the positive charge of lysines and 
decreases the interaction between histones and DNA giv-
ing rise to a more open chromatin conformation, which is 
often associated to transcription factor accessibility and 
transcriptional activation. Acetyltransferases are forming 
part of large multiprotein complexes, and most of them have 
been implicated in cancer.96,97 Lysine acetylation is read by 
proteins containing specific interacting domains termed 
bromodomains (BRDs). BRD is a motif of 110 amino acids 
that binds the ε-aminoacetyl groups of nucleosomal histone 
lysines.98,99 The BRD and extraterminal (BET) proteins 
(BRD2, BRD3, BRD4, and BRDT) contain a double BRD 
in the N-terminal region and an extraterminal (ET) protein–
protein interaction domain in the C-terminal region. BRD4 
interacts and recruits P-TEFb to the core promoter of the 
active genes. P-TEFb is composed of cyclin T1 and CDK9, a 
kinase that phosphorylates the C-terminal domain (CTD) of 
the RNA polymerase II to allow transcription elongation11,100 
(Figure 3). BRD4 aberrant expression or translocation has 
been found in different tumor types including AML.97 BRD2 
Table 3 Myc synthetic lethal interactions
MYC-SL SMIs Hematological disease Reference
Aurora kinase panAKi AS703569 eµ-Myc lymphoma cells 134
Aurora kinase vX-680 Mouse models of T-cell and B-cell lymphoma 136
CHK1 Chekin B-cell lymphoma cell lines 
eµ-Myc lymphoma cells 
λ-Myc lymphoma cells
137
CDK1 Purvalanol eµ-Myc lymphoma cells 
BL and MM cell lines
141
PiM1 SGi-1776 CLL primary patients lymphocyte 151
PiM1 SMi-4a Human pre-T-LBL cell lines 150
PiM1 Pimi Mouse B-cell lymphomas 147
Pi3K/mTORC1 BEZ235 eµ-Myc lymphoma cells 152
ATR No SMi (ATR hypomorphic × eµ-Myc) eµ-Myc lymphoma cells 
Human Burkitt lymphoma
142
wRN No SMI (WRN-deficient × eµ-Myc) eµ-Myc lymphoma cells 
Xenograft and autochthonous tumor models
145
MAPK1 No SMI (KSR1-deficient × eµ-Myc) eµ-Myc lymphoma cells 155
BeTa JQ1 AML mouse model 
AML primary patients samples 
AML cell lines 
BL and AML cells xenografted
111,112
BeTa JQ1 MM mouse model 
Patient-derived MM cells 
MM human cell line
95,109
BeTa JQ1 DLBCL and BL cell lines 
DLBCL xenografted into mouse 
ALL cell lines
114
BeTa JQ1 ALL bone marrow xenografted into mouse 43 
29
BeTa JQ1/RvX2135 eµ-Myc lymphoma cells 
λ-Myc lymphoma cells
105,106
BeTa JQ1 Primary mouse and T-ALL cell lines 25
BeTa OTX015 DLBCL cell lines 
DLBCL xenografted into mouse
103,104
Notes: aBeT proteins act upstream of MYC and thus BeT inhibition is not a canonical MYC synthetic lethal approach. They are included in the table for comprehensiveness.
Abbreviations: SMis, small molecule inhibitors; BeT, bromodomain and extra-terminal; BL, Burkitt lymphoma; MM, multiple myeloma; CLL, chronic lymphocytic 
leukemia; pre T-LBL, precursor T-cell lymphoblastic leukemia/lymphoma; AML, acute myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; ALL, acute lymphocytic 
leukemia; T-ALL, T-cell acute lymphoblastic leukemia.





and BRD4 have crucial roles in the control of cell cycle 
control in mammalian cells;101 thus, they have a promising 
potential as anticancer agents.
It has been demonstrated that MYC expression can be selec-
tively regulated with BET inhibitors. The first one was JQ1, 
which shows strong affinity for the BRD4 family member thus 
inhibiting its activity.102 Other BET inhibitors such as OTX015 
have shown their antiproliferative effects on lymphoma cells103 
and have entered clinical trials.104 Lucas et al105 have described 
the inhibitor XD14, which shows a potent antiproliferative 
effect in leukemia cells. Another BET inhibitor RVX2135 
inhibits proliferation of lymphoma cells from Eµ-Myc mice in 
vitro and in vivo.106 There are other BET inhibitors in preclini-
cal studies, such as I-BET151, active against JAK2-dependent 
myeloproliferative neoplasms,107 but that those drugs truly target 
MYC has not been demonstrated.108
Recent studies in MM indicate that BET inhibitors are 
able to cause MYC downregulation in the context of trans-
located, amplified, or wild-type (WT) MYC alleles.109,110 
Other reports show that the expression of MYC decreases in 
AML-derived cell lines with WT MYC, whereas cells with 
MYC amplification display relative resistance to the effect 
of BET inhibitors.111 Several studies have been performed 
on inhibiting BRD4, and hence MYC, in a range of hema-
tological malignancies as AML,112 MLL-fusion leukemia;113 
MM,95,109 ALL,43 B-cell lymphomas,106 BL,111 DLCBCL,114 
and T-ALL.25 The most common biological effects of MYC 
downregulation upon BET inhibition is cell cycle arrest in G
1
 
phase and apoptosis or senescence, but other effects such as 
terminal myeloid differentiation and elimination of leukemic 
stem cells have also been reported.95,109,114
One of the challenges is to understand how the inhibition 
of the activity of a general regulator such as BRD4 results in a 
selective effect on the expression of a small number of genes 
in specific cells.42,43,111 Several groups have demonstrated 
that in the case of MYC and other transcription factors, the 
specific effect is achieved because the BET inhibitor causes 
a depletion of BRD4 at the enhancers and superenhancers 
that drive the oncogene expression.95,109,114
inhibition of MYC–MAX dimerization
In parallel to the repression of MYC expression with the 
BET inhibitors, other approaches specifically targeting MYC 
transactivation activities are under study (summarized in 
Figure 4). As noted earlier, MYC is only active when forming 
a dimer with MAX, suggesting that blocking the dimeriza-
tion between MYC and MAX would be a good approach 
for inhibiting MYC function. Soucek et al115 constructed a 
MYC mutant, known as Omomyc, after identification of the 
molecular recognition site and induction of mutation of four 
amino acids at the LZ. Omomyc was able to sequester MYC 
and formed complexes with low binding efficiency to DNA, 
preventing the binding with MAX and inhibiting the function 
of MYC as a transcription factor (Figure 4B). Thus, Omomyc 
impairs MYC binding to E-boxes and changes MYC-depen-
dent expression profile toward gene repression.116 Moreover, 
studies carried out in mouse models for some solid tumors 
(pancreas, skin, lung, and glioblastoma) reveal that MYC 
is required for full tumor development, even when tumor is 
triggered by other oncogenes.93,94,117,118 No data on Omomyc in 
lymphoma or leukemia model are available yet. As Omomyc 
is a peptide, its application in clinic might be difficult due 
to low biodisponibility and penetrance into the target cells. 
These problems will more likely be overcome with small 
molecules. However, the design of small molecules targeting 
the MYC–MAX interaction site is difficult due to the large 
interface between both proteins and because of the lack of 
structural “pockets” where small molecules could bind.
Despite these difficulties, attempts have been made to 
design small molecules which would inhibit MYC–MAX 
heterodimers (Figure 4C). In a screen of approximately 7,000 
small organic molecules using FRET, two compounds were 
discovered to specifically inhibit MYC–MAX dimeriza-
tion. These compounds Mycmycin-1 and Mycmycin-2 did 
not inhibit Jun dimerization and were a proof of concept 
to develop other molecules that specifically inhibit MYC-
induced oncogenic transformation.119
A new series of compounds, 10058-F4 and 10074-G5, were 
















Figure 3 Scheme of the mechanism of action of BRD4 inhibitors as anti-MYC 
drugs. BRD4 is a reader of acetylated histones and promotes the activity of P-TeFb 
complex, composed by CDK9 and cyclin T1 (“Cyc.T” in the Figure).
Notes: P-TeFb phosphorylates the C-terminal domain (CTD) of RNA polymerase ii 
to trigger elongation. This process is impaired by BeT inhibitors. MYC would be one of 
the genes which transcription is more dependent on BRD4 and P-TeFb activity. Some 
BeT inhibitors that inhibit leukemia or lymphoma cell growth are shown at the left.
Abbreviation: BeT, bromodomain and extra-terminal.
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were able to inhibit both the growth of fibroblasts in vitro and 
growth of tumors in mice. The clinical applicability is still 
limited due to its low potency and its rapid degradation.121 The 
specificity of 10058-F4 and 10074-G5 was further corrobo-
rated by using a series of deletion and point mutations within 
the MYC bHLH-ZIP domain that resulted in the disruption of 
the heterodimer.122 Moreover, these compounds do not inhibit 
MAX  homodimerization. Improvements of these drugs were 
achieved by adding chemical modifications and, as a result, 
they have enhanced growth inhibition of MYC-expressing 
cells in a manner that generally correlates with the compound 
ability to disrupt MYC–MAX association and DNA bind-
ing.123 Another study in nontransformed embryonal stem cells 
showed that these latter compounds results in loss of expres-
sion of MYC target genes but not of non-MYC target genes.124 
The effect of 10054-F4 has been tested in AML cells, inhibit-
ing leukemic proliferation, and inducing apoptosis through 
the mitochondrial pathway. Importantly, these effects were 
reproduced in primary AML cells.125 However, AML cells are 
partially resistant to 10054-F4 when they are in contact with 
bone marrow stroma.126 Another good model to test the effect 
of 10054-F4 is MM, which shows high deregulation of MYC 
as shown earlier. The MYC–MAX inhibitor 10054-F4 was 
effective on human MM cell lines and samples from patients 
and, although there was not a good correlation between sen-
sitivity and MYC levels, cells expressing the highest levels of 
MYC tended to be more resistant to the treatment.64 All these 
results support the idea that targeting MYC dimerization is 
feasible. However, it may have the drawback that not all MYC 
functions depend on MAX.127–129
inhibitors of the binding of MYC–MAX 
to DNA
Mo et al130 performed a cellular screening to identify sub-
stances that could be used to interfere with the MYC pathway 




























Figure 4 MYC inhibition strategies based on the interruption of the MYC–MAX dimerization.
Notes: (A) MYC–MAX heterodimer in gene transactivation. (B) Blocking MYC–MAX interaction with Omomyc. (C) Blocking MYC–MAX interaction with small molecules 
as 10058-F4. (D) Blocking the binding of MYC–MAX to DNA with small molecules as MYRA.
Abbreviations: LZ, leucine zipper of MAX and MYC; TAD, N-ter transactivation domain of MYC.





WT expression, they found two compounds that selectively 
affected cell viability in MYC-overexpressing cells. They 
called the two compounds MYRA-A and MYRA-B (for 
MYC pathway response agents). MYRAs were more effective 
in human BL cells compared with other lymphoblastoid cell 
lines. Using three human cell lines with different levels of 
MYC (WT, null, or overexpressed), they found that MYRAs 
induced a high apoptotic state in cells overexpressing MYC, 
indicating that the effects of the compounds on cell viability 
is MYC-dependent.
MYRA-A interfered with the DNA binding of MYC–
MAX (by electrophoretic mobility shift assays) but not 
with another E-box binding factor, USF, demonstrating that 
the inhibition was specific. Furthermore, they showed by 
coimmunoprecipitation that the MYC–MAX heterodimer 
remained intact after the treatment with MYRA-A. Recently, 
a new series of molecules interrupting the binding of MYC–
MAX to DNA have been reported.131 These compounds 
inhibit MYC-dependent transactivation (by luciferase 
assays) in the µM range although MYC–MAX heterodimers 
remained intact.
MYC-mediated synthetic lethality
An alternative approach to target MYC is based on “synthetic 
lethality”. Synthetic lethal screens have been used to identify 
genes and pathways that are selectively activated by MYC in 
tumors, but not in nontumorigenic cells. Thus these molecules 
can be targeted with inhibitors to control MYC-driven malig-
nancies. As expected from the multiplicity of the pathways 
in which MYC is involved, large series of putative synthetic 
lethal genes have been identified.132,133 We will review some 
of the MYC synthetic lethal interactions assayed in leukemia 
and lymphoma, which are also summarized in Table 3.
Aurora kinase inhibitors
MYC regulates aurora kinase A (AURKA) and B (AURKB) 
in the Eµ-Myc mouse model.134 Both kinases play a pivotal 
role in mitosis. Expression of MYC, but not other oncogenes, 
made the cells much more sensitive to Aurora kinase inhibi-
tors (eg, AS703569), AURKB being the central target in this 
model. Another aurora kinase inhibitor, VX-680, was demon-
strated to selectively kill the cells that overexpress MYC.135 
Indeed, MYC expression levels may provide a biomarker 
to identify tumors that may be respond to aurora kinase B 
inhibitors. Moreover, the drug inhibited AURKB in vivo in 
mouse models that develop either B-cell or T-cell lymphomas 
in response to MYC overexpression.136 Furthermore, the lethal 
response is independent of p53-p21 pathway.136 This fact is 
relevant since TP53 is frequently mutated in different tumors 
and usually confers an adverse prognosis.
Chk1 inhibitors
One of the effects of MYC overexpression is to induce DNA 
replicative stress, which in turn activates CHK1 (checkpoint 
kinase 1). In cells from human and murine B-cell lympho-
mas, there is a correlation between MYC and CHK1 levels, 
although CHK1 seems to be an indirect target of MYC.137 
Silencing of CHK1 with siRNA technology or inactivation 
with a small molecule (Chekin) results in selective death of 
MYC-overexpressing cells. These evidences turned CHK1 
into an attractive therapeutic target. When tested in the 
λ-Myc mouse model, Chekin was able to induce a signifi-
cantly slower disease progression followed by death in this 
lymphoma model.137
CDK1 inhibitors
The CDKs together with the cyclins form complexes that 
regulate cell cycle, both in neoplastic and normal cells. CDK1 
is essential for mammalian cell division,138 and, as a matter 
of fact, is the only CDK required for cell cycling.139 Small 
molecule inhibitors have been developed against CDKs which 
induce cell cycle arrest in G
2
 phase.140 However, in MYC over-
expressing cells, these drugs induce apoptosis,141 indicating 
that CDK1 inhibition is synthetically lethal on MYC express-
ing cells. Accordingly, a CDK1 inhibitor induces cell death in 
BL and MM cell lines depending on MYC levels, and CDK1 
inhibition in Eµ-Myc mice results in extended survival.141
ATR inhibitors
Like CHK1, ATR kinase plays a pivotal role in replicative 
stress response. Myc-induced lymphomas in the Eµ-myc 
mice show a high level of replicative stress. The synthetic 
lethality between ATR and MYC has been demonstrated in 
a model of Eµ-myc mice crossed with mice with low ATR 
expression. In these mice, MYC-driven lymphomagenesis 
was suppressed.142 Preclinical data with highly specific ATR 
inhibitors have opened up the possibility of using them in 
synthetic lethality approaches.143
wRN inhibitors
WRN is a gene encoding a RecQ DNA helicase that is a direct 
transcriptional target of MYC. Even though WRN mutations 
have not been found in tumors, it has been reported that WRN 
is overexpressed in cancer cell lines from BL.144 Also, in BL 
cells, knock down of WRN impairs cell proliferation and 
increases apoptosis.144 In the same line of evidence, muta-
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tion of WRN in Eµ-Myc mouse models results in an increase 
in tumor-free survival and a delay in emergence of lethal 
lymphomas.145 These results demonstrate that using WRN 
as a target could result in an effective strategy not only to 
treat MYC-associated hematological diseases but also other 
MYC-associated cancers.
PiM kinases inhibitors
PIM kinases (1, 2, and 3) are involved in B-cell development 
and in hematologic malignancies.146,147 The PIM kinases, 
when coexpressed with MYC, provoke an acceleration of 
tumorigenesis.147 Given the fact that PIM1148 and MYC are 
overexpressed in lymphomas and that PIM1 is a coactivator 
of MYC,149 there has been an interest in developing PIM 
kinase inhibitors. A PIM kinase inhibitor (SMI-4a) kills sev-
eral myeloid and lymphoid cell lines, with higher activity on 
T-cell lymphoblastic leukemia/lymphoma.150 Another inhibi-
tor (SGI-1776) induces cytotoxicity in primary lymphocytes 
from CLL patients.151 Finally, a pan-Pim kinase inhibitor 
(Pimi) causes a reduction in mouse BL cell lines proliferation 
and a reduction in MYC-regulated transcripts.147
Pi3K/TORC1 inhibitors
MYC-driven lymphomas demonstrate activation of mTORC1 
and an endogenous DNA damage response. The small mol-
ecule BEZ235 inhibits both the PI3K-related DNA damage 
response kinases and mTORC1. This inhibitor shows a 
potent cytotoxic activity against Myc-driven B-cell lym-
phomas and BL-derived human cell lines bearing IG-cMYC 
translocations.152
MAPK inhibitors
The activation of the RAS-MEK-MAPK pathway results in 
MYC protein stabilization, which is mediated by the MAPK-
dependent phosphorylation of a Ser residue in the MYC 
N-terminal region.153 Some reports suggest that MAPK inhi-
bition may induce a synthetic lethal interaction with MYC. 
Indeed, the first example of oncogenic cooperation reported was 
that of MYC and RAS in the transformation of primary mouse 
fibroblasts.154 More recently, it has been shown that the impair-
ment of RAS–MAPK pathway in mice deficient for KSR1 gene 
(encoding a scaffold protein of MAPK) results in a decrease in 
Myc-induced lymphomagenesis in a murine model.155
Conclusion
Deregulation of MYC oncogene is a pervasive finding in 
leukemia and lymphoma, in many cases inducing tumor 
progression and conferring poor prognosis. Cell culture 
studies and mouse transgenic models have shown that MYC 
plays a pivotal role in initiation and development of many 
types of hematological neoplasms. Thus, MYC would be a 
good therapeutic target in leukemia and lymphoma. As is 
the case for other transcription factors, the development of 
small molecules inhibiting MYC activity has been difficult. 
However, in recent years, different approaches targeting MYC 
have been described. These are based on the impairment of 
MYC expression (BET inhibitors), small molecules blocking 
MYC transactivation function, or synthetic lethal approaches. 
Altogether, the data suggest that MYC inhibition could be 
a clinically feasible strategy for leukemia and lymphoma 
therapy and that therapies targeting MYC are in sight.
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